Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Enasidenib for IDH2-mutated MDS

Valeria Santini • 17 Mar 2020
Myelodysplastic Syndromes Enasidenib

Valeria Santini, MD, University of Florence, Florence, Italy, gives us a round-up of some of the exciting trials currently taking place in the myelodysplastic syndromes (MDS) space. Specifically, Dr Santini outlined the use of enasidenib for IDH2-mutated MDS. This interview was filmed via an online conference call with VJHemOnc.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals